×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IRWD – ironwood pharmaceuticals, inc. - class a (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IRWD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/13
04:01 pm
irwd
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
Medium
Report
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
11/12
02:01 am
irwd
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Medium
Report
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
11/8
04:10 am
irwd
Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
Medium
Report
Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
11/8
12:03 am
irwd
Ironwood Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation [Seeking Alpha]
Medium
Report
Ironwood Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation [Seeking Alpha]
11/7
07:00 am
irwd
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
Medium
Report
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
11/6
07:41 am
irwd
Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Report Preview: What To Expect [Yahoo! Finance]
Medium
Report
Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Report Preview: What To Expect [Yahoo! Finance]
11/4
11:12 pm
irwd
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Medium
Report
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
10/28
07:00 am
irwd
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
Neutral
Report
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
Date
Time
Symbol
Company Name
Action
%Chg
11/7/2024
07:00 am
IRWD
ironwood pharmaceuticals, inc. - class a
MISS
Report
-7.5%
ironwood pharmaceuticals, inc. - class a
8/8/2024
07:00 am
IRWD
ironwood pharmaceuticals, inc. - class a
MISS
Report
-30.7%
ironwood pharmaceuticals, inc. - class a
5/9/2024
07:00 am
IRWD
ironwood pharmaceuticals, inc. - class a
MISS
Report
-13.1%
ironwood pharmaceuticals, inc. - class a
2/15/2024
07:00 am
IRWD
ironwood pharmaceuticals, inc. - class a
MISS
Report
-4.9%
ironwood pharmaceuticals, inc. - class a
Date
Time
Symbol
Headline
Impact
11/20
04:05 pm
irwd
Form 4 IRONWOOD PHARMACEUTICALS For: Nov 18 Filed by: Emany Sravan Kumar
Medium
Report
Form 4 IRONWOOD PHARMACEUTICALS For: Nov 18 Filed by: Emany Sravan Kumar
11/20
04:05 pm
irwd
Form 4 IRONWOOD PHARMACEUTICALS For: Nov 18 Filed by: Davis Andrew
Medium
Report
Form 4 IRONWOOD PHARMACEUTICALS For: Nov 18 Filed by: Davis Andrew
11/15
04:10 pm
irwd
Form 144 IRONWOOD PHARMACEUTICALS Filed by: Davis Andrew
Medium
Report
Form 144 IRONWOOD PHARMACEUTICALS Filed by: Davis Andrew
11/15
04:07 pm
irwd
Form 144 IRONWOOD PHARMACEUTICALS Filed by: Emany Sravan Kumar
Medium
Report
Form 144 IRONWOOD PHARMACEUTICALS Filed by: Emany Sravan Kumar
11/14
03:32 pm
irwd
Form SC 13G IRONWOOD PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G IRONWOOD PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC
11/13
02:42 pm
irwd
Form SCHEDULE 13G IRONWOOD PHARMACEUTICALS Filed by: RENAISSANCE TECHNOLOGIES LLC
Low
Report
Form SCHEDULE 13G IRONWOOD PHARMACEUTICALS Filed by: RENAISSANCE TECHNOLOGIES LLC
11/12
04:06 pm
irwd
Form 8-K IRONWOOD PHARMACEUTICALS For: Nov 06
Low
Report
Form 8-K IRONWOOD PHARMACEUTICALS For: Nov 06
11/12
03:48 pm
irwd
Form SC 13G/A IRONWOOD PHARMACEUTICALS Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A IRONWOOD PHARMACEUTICALS Filed by: VANGUARD GROUP INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/16
Form SC 13D IRONWOOD PHARMACEUTICALS Filed by: Sarissa Capital Management LP
11.5%
4/14 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.5%
2/26 Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology 7.5%
10/31 Q3/2019 9/30/2019 EPS 0.400 ZacksConsensus 0.100 ActVsEst 0.300 - Beat 6.5%
1/6 Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation 6.3%
9/11 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.8%
2/29 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.4%
2/13 Q4/2019 12/31/2019 EPS 0.300 ZacksConsensus 0.220 ActVsEst 0.080 - Beat 4.9%
5/31 Form 4 IRONWOOD PHARMACEUTICALS For: May 29 Filed by: Dreyfus Andrew 4.5%
8/13 Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP) 3.9%
4/14 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.5%
2/26 Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology 7.5%
10/31 Q3/2019 9/30/2019 EPS 0.400 ZacksConsensus 0.100 ActVsEst 0.300 - Beat 6.5%
1/6 Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation 6.3%
9/11 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.8%
2/29 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.4%
2/13 Q4/2019 12/31/2019 EPS 0.300 ZacksConsensus 0.220 ActVsEst 0.080 - Beat 4.9%
5/31 Form 4 IRONWOOD PHARMACEUTICALS For: May 29 Filed by: Dreyfus Andrew 4.5%
8/13 Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP) 3.9%
TOP News Decliners
3/17
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 13 Filed by: Dreyfus Andrew
-10.8%
7/31 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock, up previously from $11.00. -9.1%
2/14 Form SC 13G/A IRONWOOD PHARMACEUTICALS Filed by: BROWN CAPITAL MANAGEMENT LLC -6.2%
6/18 Form 4 IRONWOOD PHARMACEUTICALS For: Jun 14 Filed by: Dreyfus Andrew -5.9%
6/13 Form 8-K IRONWOOD PHARMACEUTICALS For: Jun 11 -5.5%
8/6 Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes -5.2%
3/2 Form 4 IRONWOOD PHARMACEUTICALS For: Feb 27 Filed by: MacDonald Kelly -3.6%
10/17 Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call -3.5%
8/13 Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment -3.5%
4/15 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its price target lowered by analysts at Morgan Stanley from $13.00 to $12.00. They now have an "equal weight" rating on the stock. -3.2%
7/31 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock, up previously from $11.00. -9.1%
2/14 Form SC 13G/A IRONWOOD PHARMACEUTICALS Filed by: BROWN CAPITAL MANAGEMENT LLC -6.2%
6/18 Form 4 IRONWOOD PHARMACEUTICALS For: Jun 14 Filed by: Dreyfus Andrew -5.9%
6/13 Form 8-K IRONWOOD PHARMACEUTICALS For: Jun 11 -5.5%
8/6 Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes -5.2%
3/2 Form 4 IRONWOOD PHARMACEUTICALS For: Feb 27 Filed by: MacDonald Kelly -3.6%
10/17 Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call -3.5%
8/13 Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment -3.5%
4/15 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its price target lowered by analysts at Morgan Stanley from $13.00 to $12.00. They now have an "equal weight" rating on the stock. -3.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: